Cargando…
(225)Ac-rHDL Nanoparticles: A Potential Agent for Targeted Alpha-Particle Therapy of Tumors Overexpressing SR-BI Proteins
Actinium-225 and other alpha-particle-emitting radionuclides have shown high potential for cancer treatment. Reconstituted high-density lipoproteins (rHDL) specifically recognize the scavenger receptor B type I (SR-BI) overexpressed in several types of cancer cells. Furthermore, after rHDL-SR-BI rec...
Autores principales: | Hernández-Jiménez, Tania, Ferro-Flores, Guillermina, Morales-Ávila, Enrique, Isaac-Olivé, Keila, Ocampo-García, Blanca, Aranda-Lara, Liliana, Santos-Cuevas, Clara, Luna-Gutiérrez, Myrna, De Nardo, Laura, Rosato, Antonio, Meléndez-Alafort, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000893/ https://www.ncbi.nlm.nih.gov/pubmed/35408554 http://dx.doi.org/10.3390/molecules27072156 |
Ejemplares similares
-
Engineered rHDL Nanoparticles as a Suitable Platform for Theranostic Applications
por: Aranda-Lara, Liliana, et al.
Publicado: (2022) -
rHDL modeling and the anchoring mechanism of LCAT activation
por: Laurenzi, Tommaso, et al.
Publicado: (2020) -
Development of (177)Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen
por: Carpanese, Debora, et al.
Publicado: (2020) -
Pre-Clinical Evaluation of rHDL Encapsulated Retinoids for the Treatment of Neuroblastoma
por: Sabnis, Nirupama, et al.
Publicado: (2013) -
Synergetic Effect of rHDL and LXR Agonist on Reduction of Atherosclerosis in Mice
por: Morin, Emily E., et al.
Publicado: (2020)